{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:42:46Z","timestamp":1777398166899,"version":"3.51.4"},"reference-count":53,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,11,21]],"date-time":"2005-11-21T00:00:00Z","timestamp":1132531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>To overcome the ototoxicity of cisplatin, single bolus infusions were replaced by repeated prolonged infusions of lower doses or by continuous infusions at still lower infusion rates. However, considering ototoxicity little is, in fact, known about the tolerance of repeated prolonged or continuous infusion in children.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>Auditory function was monitored along with plasma concentrations of free and total platinum (Pt), and with standard serum parameters (sodium, potassium, calcium, magnesium, phosphate, chloride, and creatinine) in 24 children receiving cisplatin by continuous infusion for the treatment of neuroblastoma and osteosarcoma or by repeated 1 or 6 hr infusions for the treatment of germ cell tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Hearing deteriorated in 10\/15 osteosarcoma patients, 2\/3 neuroblastoma patients, and 1\/6 patients with germ cell tumors. Ototoxicity occurred after cumulative doses between 120 and 360 mg\/m<jats:sup>2<\/jats:sup> cisplatin. In osteosarcoma patients, ototoxicity was associated with a comparatively higher mean plasma concentration of free Pt. However, Pt plasma concentrations did not discriminate between patients with or without ototoxicity. In patients experiencing ototoxicity serum creatinine increased by 45% compared to pre\u2010treatment levels (mean). Serum creatinine increased by 26% in patients without ototoxicity (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05, Mann\u2013Whitney Rank sum test). Despite standardized hydration, discrete but significant changes of potassium, sodium, magnesium, and phosphate were observed during and\/or after cisplatin infusion, which, however, did not discriminate between patients with and without ototoxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>While continuous cisplatin infusions are less nephrotoxic than repeated prolonged infusions, we observed considerable ototoxicity in patients treated with continuous cisplatin infusions, which necessitates further evaluations on the tolerance of continuous cisplatin infusions in children. Pediatr Blood Cancer \u00a9 2005 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.20673","type":"journal-article","created":{"date-parts":[[2005,11,21]],"date-time":"2005-11-21T20:47:44Z","timestamp":1132606064000},"page":"183-193","source":"Crossref","is-referenced-by-count":54,"title":["Continuous or repeated prolonged cisplatin infusions in children: A prospective study on ototoxicity, platinum concentrations, and standard serum parameters"],"prefix":"10.1002","volume":"47","author":[{"given":"C.","family":"Lanvers\u2010Kaminsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Krefeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.G.","family":"Dinnesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Deuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"W\u00fcrthwein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Jaehde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.C.","family":"Pieck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Boos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,11,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950190415"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-199007000-00008"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199906000-00020"},{"key":"e_1_2_6_5_2","first-page":"19","article-title":"Ototoxicity in patients receiving cisplatin: Importance of dose and method of drug administration","volume":"66","author":"Reddel RR","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-199109000-00001"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-199911000-00016"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/019459989310900302"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199903000-00007"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-199109000-00010"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199701)28:1<35::AID-MPO7>3.0.CO;2-U"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000168288"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)83372-4"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10335"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.1999.0097"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.276"},{"key":"e_1_2_6_17_2","first-page":"1663","article-title":"Cisplatin and platinum drugs at the molecular level. (Review)","volume":"10","author":"Boulikas T","year":"2003","journal-title":"Oncol Rep"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(00)00584-0"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206933"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.296"},{"key":"e_1_2_6_21_2","first-page":"35","article-title":"Covalent binding of platinum to renal protein from sensitive and resistant guinea pigs treated with cisplatin: Possible role in nephrotoxicity","volume":"61","author":"Litterst CL","year":"1988","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1992.tb00445.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5955(96)00126-8"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5955(96)00075-5"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1994.01880290051009"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(83)80551-4"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851015)56:8<1934::AID-CNCR2820560807>3.0.CO;2-F"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004670100610"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197811)42:5<2135::AID-CNCR2820420508>3.0.CO;2-W"},{"key":"e_1_2_6_30_2","first-page":"905","article-title":"Phase I study of cis\u2010diamminedichloroplatinum(II) administered as a constant 5\u2010day infusion","volume":"64","author":"Lokich JJ","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870101)59:1<15::AID-CNCR2820590107>3.0.CO;2-Q"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840215)53:4<837::AID-CNCR2820530403>3.0.CO;2-L"},{"key":"e_1_2_6_33_2","article-title":"The \u201cMuenster classification\u201d of high frequency hearing loss following cisplatin chemotherapy","author":"Schmidt C\u2010M","year":"2005","journal-title":"HNO"},{"key":"e_1_2_6_34_2","first-page":"11","article-title":"Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy","volume":"36","author":"American Speech\u2010Language\u2010Hearing Association","year":"1994","journal-title":"Asha"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199912000-00009"},{"key":"e_1_2_6_36_2","volume-title":"Labor und diagnose","author":"Thomas L"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.06.003"},{"key":"e_1_2_6_38_2","first-page":"742","article-title":"Auditory function in pediatric osteosarcoma patients treated with multiple doses of cis\u2010diamminedichloroplatinum(II)","volume":"49","author":"Ruiz L","year":"1989","journal-title":"Cancer Res"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.08.009"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.3109\/00016487309139733"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00857658"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004670050507"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19811015)48:8<1715::AID-CNCR2820480805>3.0.CO;2-Y"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00689694"},{"key":"e_1_2_6_45_2","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1200\/JCO.1986.4.12.1787","article-title":"High\u2010dose cisplatin in hypertonic saline: Reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non\u2010small\u2010cell lung cancer","volume":"4","author":"Gandara DR","year":"1986","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1177\/009127002401102704"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(86)80020-8"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-90-6-929"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1992.00400130066006"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.3109\/08880018709141287"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601344"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1999.tb00278.x"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2004.pto940508.x"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90523-J"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.20673","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.20673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T03:01:00Z","timestamp":1697166060000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.20673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,21]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1002\/pbc.20673"],"URL":"https:\/\/doi.org\/10.1002\/pbc.20673","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,21]]}}}